Here are the 10-K annual reports from COMPASS Pathways Plc (CMPS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow CMPS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CMPS filings page.
Compass Pathways is a clinical-stage biotech focused on its investigational COMP360 psilocybin treatment for serious mental health conditions, primarily treatment‑resistant depression (TRD) and PTSD. The company completed enrollment in two Phase 3 TRD trials and reported that both achieved their primary endpoints on the MADRS depression scale.
In COMP005, a single 25 mg dose of COMP360 showed a highly statistically significant and clinically meaningful MADRS improvement versus placebo at week 6, with durable effects through 26 weeks after one or two doses. In COMP006, two 25 mg doses given three weeks apart outperformed 1 mg on MADRS at week 6, also with rapid onset. COMP360 has generally shown a tolerable safety profile, with most adverse events mild or moderate and resolving within a day.
Based on these data, Compass plans to complete a rolling NDA submission for TRD in the fourth quarter of 2026 and is accelerating U.S. launch planning. The FDA has also accepted an IND for a Phase 2b/3 PTSD trial after an open‑label Phase 2 study showed large, durable reductions in CAPS‑5 PTSD severity and functional impairment.